Intratumoral and peritumoral MRI habitat imaging for differentiating stage IA endometrial cancer from benign endometrial lesions: a multicenter study - Scorecard - MDSpire
Advertisement
Intratumoral and peritumoral MRI habitat imaging for differentiating stage IA endometrial cancer from benign endometrial lesions: a multicenter study
Clinical Scorecard: MRI Habitat Imaging of Intratumoral and Peritumoral Regions for Distinguishing Stage IA Endometrial Cancer from Benign Endometrial Lesions: A Multicenter Analysis
At a Glance
Category
Detail
Condition
Stage IA Endometrial Cancer
Key Mechanisms
Multiparametric MRI-based radiomics models for tumor differentiation
Target Population
Patients diagnosed with stage IA endometrial cancer or benign endometrial lesions
Care Setting
Multicenter retrospective study
Key Highlights
Study included 787 patients from four centers
Age and vaginal bleeding identified as independent predictors of stage IA EC
Habitat-based models outperformed clinical models in external validation cohorts
Combined clinical and habitat model achieved peak AUC of 0.921
K-means clustering demonstrated superior robustness compared to GMM
Guideline-Based Recommendations
Diagnosis
Utilize multiparametric MRI for non-invasive differentiation of stage IA EC from benign lesions
Management
Consider integrating clinical predictors with habitat imaging for improved diagnostic accuracy
Monitoring & Follow-up
Monitor the performance of habitat-based models in clinical practice
Risks
Traditional diagnostic modalities are invasive and may have sampling errors
Patient & Prescribing Data
Women diagnosed with stage IA endometrial cancer or benign endometrial lesions
Non-invasive imaging approaches may guide treatment decisions and mitigate overtreatment
Clinical Best Practices
Employ habitat imaging to assess intratumoral and peritumoral characteristics
Use a combination of clinical and imaging data for diagnosis
